Latest results FY2025 · Prices updated Oct 30, 2026
HQ: Chiyoda-ku, TokyoFounded 19494,013 employeesWebsite
A leading pharmaceutical company under the Kirin Group. Specializes in biotechnology to develop and commercialize innovative drugs globally in nephrology, oncology, and immunology.
Latest results
FY2025
vs. same period a year earlier
Company forecastFY2026
Close (Oct 30, 2026)
¥2,464+7.1% (1Y)
Kyowa Kirin +7.1% over 1Y, 5.7pt below the industry average (23 companies, +12.8%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2025FY | ¥496.8B | — | ¥67.0B | ¥1.1T | +0.2% |
| 2024FY | ¥495.6B | — | ¥59.9B | ¥1.1T | +12.1% |
| 2023FY | ¥442.2B | — | ¥81.2B | ¥1.0T | +11.0% |
| 2022FY | ¥398.4B | — | ¥53.6B | ¥939.9B | +13.1% |
| 2021FY | ¥352.2B | — | ¥52.3B | ¥921.9B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
